Welcome to our new website. We have rebranded from Lamepro to Pharmanovia Benelux

5th April 2022

Life cycle management company Pharmanovia launches its inaugural sustainability report

The report celebrates the firm’s diversity and sets out ambitious environmental and sustainability targets London April…

More information
29th March 2022

Pharmanovia announces departure of Chief Corporate Development Officer Alastair Hay

LONDON – Alastair Hay is leaving his position as Chief Corporate Development Officer at the global…

More information
28th February 2022

Pharmanovia Announces Rebrand of its Benelux Business to Pharmanovia Benelux

Pharmanovia officially welcomes Lamepro B.V into the group Basildon (UK), 28 February 2022 – Pharmanovia, The life…

More information
12th November 2021

Pharmanovia to present at the Jefferies 2021 London Healthcare Conference

Basildon (UK), 10 November 2021 – Pharmanovia, the original medicines specialist globally, today announced that its…

More information
8th September 2021

Pharmanovia launches OsteoApp, creating new ways to improve the management of osteoporosis

Basildon (UK), 8 September 2021 – Pharmanovia, the original medicines specialist globally, in conjunction with their…

More information
2nd August 2021

Pharmanovia Announces Global Charity Partnership with HIPZ

Basildon (UK), 30 July, 2021 – Pharmanovia is proud to announce their first global charity partnership…

More information
21st July 2021

Pharmanovia Expands Strategic Collaboration with M8 Pharmaceuticals in Latin America

Basildon (UK), 20 July, 2021 – m8 Pharmaceuticals and Pharmanovia have signed an exclusive licensing agreement…

More information
12th July 2021

Pharmanovia Announces CEO Transition Plan

Amit Patel is retiring as CEO, will transition to the Advisory Committee James Burt will take…

More information
3rd June 2021

Pharmanovia Promotes Alessandro Insalata to Chief Commercial Officer

Basildon (UK), 3 June 2021 – Pharmanovia, the original medicines specialist globally announced the promotion of…

More information
3rd May 2021

The Original Medicines Specialist Rebrands to Pharmanovia

Basildon (UK), 4 May 2021 – Atnahs, the original medicines specialist backed by PE investor Triton Partners,…

More information
22nd March 2021

Atnahs Appoints New Chief Financial Officer

Basildon (UK), 22 March 2021 – Atnahs has appointed Felipe Florez to the position of Chief Financial…

More information
1st December 2020

Atnahs Acquires Rights to Valium®

Basildon (UK), 1 December 2020 – Atnahs (“Atnahs”), has acquired the commercial rights for Valium® (Diazepam) in…

More information
19th March 2020

COVID-19: Atnahs Continues Operations

Basildon (UK), 19 March 2020  – On 11 March 2020 the World Health Organization (WHO) declared…

More information
19th March 2020

Atnahs Acquires Rights to Rocaltrol®, An Established Brand in Women’s Health

Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company,…

More information
6th February 2020

Atnahs Buys Takeda Out of License Agreement for Bonviva® in Asia

Basildon (UK), 6 February 2020 – Atnahs has bought Takeda out of a license agreement for…

More information